Osocimab, formerly known as BAY 1213790, represents a unique monoclonal immunoglobulin currently undergoing clinical assessment for the treatment of multiple hematologic malignancies. This agent primarily targets CD38, https://monicaphoo906315.blog5.net/93281736/osocimab-a-deep-examination-into-bay-1213790-and-its-promise